This page shows the latest CRS-207 news and features for those working in and with pharma, biotech and healthcare.
The immunotherapy combines CRS-207 - a drug that promotes the expression of the tumour-associated antigen mesothelin - with an immune-boosting GVAX cell line, and is Aduro's lead product candidate. ... The regimen was unable to improve overall survival
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...